Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Guang Peng

Showing results (331-340 of 381) with videos related to

Pageof 39
Sort By:
Molecular Cancer Therapeutics|May 31, 2019
The DNA Endonuclease Mus81 Regulates ZEB1 Expression and Serves as a Target of BET4 Inhibitors in Gastric CancerYuping Yin, Weizhen Liu, Qian Shen, et al.
American Journal of Cancer Research|December 9, 2020
Genetic alterations and expression characteristics of ARID1A impact tumor immune contexture and survival in early-onset gastric cancerJun Zou, Wan Qin, Lin Yang, et al.
Nature Communications|March 8, 2024
GRB2 stabilizes RAD51 at reversed replication forks suppressing genomic instability and innate immunity against cancerZu Ye, Shengfeng Xu, Yin Shi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 25, 2021
ATR Inhibition Induces CDK1-SPOP Signaling and Enhances Anti-PD-L1 Cytotoxicity in Prostate CancerZhe Tang, Patrick G Pilié, Chuandong Geng, et al.
Orphanet Journal of Rare Diseases|January 15, 2025
Liver transplantation for homozygous familial hypercholesterolemia: a retrospective analysis from Chinese experienceHao-Su Zhan, Lin Wei, Wei Qu, et al.
International Journal of Surgery (London, England)|August 14, 2023
Impact of immunosuppression level on liver allograft fibrosis after pediatric liver transplantation: a retrospective cohort studyYi-Zhou Jiang, Xin-Yan Zhao, Guang-Peng Zhou, et al.
Cancer Research|February 16, 2021
MEK Inhibition Remodels the Immune Landscape of Mutant <i>KRAS</i> Tumors to Overcome Resistance to PARP and Immune Checkpoint InhibitorsBin Yang, Xi Li, Yu Fu, et al.
Cancer Discovery|June 13, 2015
ARID1A Deficiency Impairs the DNA Damage Checkpoint and Sensitizes Cells to PARP InhibitorsJianfeng Shen, Yang Peng, Leizhen Wei, et al.
The Journal of Clinical Investigation|October 5, 2020
Inhibition of the ATM/Chk2 axis promotes cGAS/STING signaling in ARID1A-deficient tumorsLulu Wang, Lin Yang, Chen Wang, et al.
Nature Communications|February 21, 2014
Genome-wide transcriptome profiling of homologous recombination DNA repairGuang Peng, Curtis Chun-Jen Lin, Wei Mo, et al.
Pageof 39

Showing results (331-340 of 381) with videos related to

Sort By:
Pageof 39
Molecular Cancer Therapeutics|May 31, 2019
The DNA Endonuclease Mus81 Regulates ZEB1 Expression and Serves as a Target of BET4 Inhibitors in Gastric CancerYuping Yin, Weizhen Liu, Qian Shen, et al.
American Journal of Cancer Research|December 9, 2020
Genetic alterations and expression characteristics of ARID1A impact tumor immune contexture and survival in early-onset gastric cancerJun Zou, Wan Qin, Lin Yang, et al.
Nature Communications|March 8, 2024
GRB2 stabilizes RAD51 at reversed replication forks suppressing genomic instability and innate immunity against cancerZu Ye, Shengfeng Xu, Yin Shi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 25, 2021
ATR Inhibition Induces CDK1-SPOP Signaling and Enhances Anti-PD-L1 Cytotoxicity in Prostate CancerZhe Tang, Patrick G Pilié, Chuandong Geng, et al.
Orphanet Journal of Rare Diseases|January 15, 2025
Liver transplantation for homozygous familial hypercholesterolemia: a retrospective analysis from Chinese experienceHao-Su Zhan, Lin Wei, Wei Qu, et al.
International Journal of Surgery (London, England)|August 14, 2023
Impact of immunosuppression level on liver allograft fibrosis after pediatric liver transplantation: a retrospective cohort studyYi-Zhou Jiang, Xin-Yan Zhao, Guang-Peng Zhou, et al.
Cancer Research|February 16, 2021
MEK Inhibition Remodels the Immune Landscape of Mutant <i>KRAS</i> Tumors to Overcome Resistance to PARP and Immune Checkpoint InhibitorsBin Yang, Xi Li, Yu Fu, et al.
Cancer Discovery|June 13, 2015
ARID1A Deficiency Impairs the DNA Damage Checkpoint and Sensitizes Cells to PARP InhibitorsJianfeng Shen, Yang Peng, Leizhen Wei, et al.
The Journal of Clinical Investigation|October 5, 2020
Inhibition of the ATM/Chk2 axis promotes cGAS/STING signaling in ARID1A-deficient tumorsLulu Wang, Lin Yang, Chen Wang, et al.
Nature Communications|February 21, 2014
Genome-wide transcriptome profiling of homologous recombination DNA repairGuang Peng, Curtis Chun-Jen Lin, Wei Mo, et al.
Pageof 39